Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770376 | 1.00 | GRM1 (0.73) | GRM1NR3C1ARLMNAHTT | |
| SCHEMBL7422783 | 0.92 | GRM1 (0.67) | GRM1 | |
| SCHEMBL7416569 | 0.87 | GRM1 (0.61) | GRM1OPRM1OPRK1 | |
| SCHEMBL6770051 | 0.86 | GRM1 (0.67) | GRM1 | |
| SCHEMBL6898189 | 0.86 | GRM1 (0.67) | GRM1NR3C1AR | |
| SCHEMBL6898191 | 0.86 | GRM1 (0.67) | GRM1NR3C1AR | |
| SCHEMBL6771084 | 0.86 | GRM1 (0.63) | GRM1L3MBTL1 | |
| SCHEMBL29360760 | 0.85 | GRM1 (1.00) | GRM1MAOBMAOA | |
| SCHEMBL186260 | 0.85 | GRM1 (1.00) | GRM1MAOBMAOA | |
| SCHEMBL6770377 | 0.84 | GRM1 (0.64) | GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723718-B2 | GLUTAMATERGIC ANTAGONIST AND AGONISTS; ANTIISCHEMIC AND ANTISPASMODIC AGENTS; BRAIN AND NERVOUS SYSTEM DISORDERS; TRAUMA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | STOLLE ANDREAS (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6462074-B1 | Substituted α, β-anellated butyrolactones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1047684-B1 | SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES | BAYER AG (DE) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | GABRB2, GABRB3, GABRB1 | GRM1 74/4885NR3C1 887/4885AR 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.